Is CRSP a Buy? What to Consider in 2026
Short answer
The bull case for CRISPR Therapeutics AG (CRSP) rests on First-Mover Advantage in Commercial Gene Editing: Casgevy is the world's first approved CRISPR-based medicine, giving CRISPR Therapeutics a durable head start in manufacturing know-how, regulatory relationships, and patient community trust. Revenue (Full Year 2025, product only) is ~$3.5 million. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. Whether CRSP is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves. CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, a Nobel Prize laureate in Chemistry, alongside Shaun Foy and Rodger Novak. It went public on the Nasdaq in October 2016 and entered a landmark collaboration with Vertex Pharmaceuticals in 2015 that ultimately led to Casgevy's FDA approval in December 2023 for sickle cell disease and in January 2024 for transfusion-dependent beta-thalassemia. The company has been led since December 2017 by CEO and Chairman Samarth (Sam) Kulkarni, a former McKinsey partner with a PhD background who joined in 2015 as Chief Business Officer. Under his leadership the pipeline has expanded into next-generation allogeneic CAR-T programs (CTX112, CTX131), in vivo cardiovascular gene editing (CTX310, CTX320), and in May 2025 the company paid $95 million upfront to acquire CTX611, a clinical-stage siRNA therapy for thrombosis prevention.
What's the case for buying CRSP?
First-Mover Advantage in Commercial Gene Editing
Casgevy is the world's first approved CRISPR-based medicine, giving CRISPR Therapeutics a durable head start in manufacturing know-how, regulatory relationships, and patient community trust. No direct CRISPR competitor has yet reached commercial approval for the same indications. That first-mover status matters because gene therapy infrastructure, including certified treatment centers and payer contracting, takes years to build.
Casgevy's Long-Term Revenue Potential
Sickle cell disease affects an estimated 100,000 patients in the United States alone, and transfusion-dependent beta-thalassemia adds tens of thousands more globally. Analysts have modeled Casgevy's peak annual sales in the billions of dollars if reimbursement access broadens and the treatment process is simplified. Reimbursement agreements are expanding in multiple countries, and Vertex's global commercial infrastructure handles the rollout.
Diversified Pipeline with Blockbuster Potential
Beyond Casgevy, clinical-stage CAR-T programs CTX112 and CTX131 target B-cell malignancies and autoimmune diseases, with broad data updates anticipated in 2025 and 2026. In vivo cardiovascular candidates CTX310 and CTX320 target ANGPTL3 and LPA respectively, addressing large patient populations. The 2025 acquisition of CTX611, a long-acting siRNA therapy silencing Factor XI for thrombosis prevention, further widens the addressable market.
Strong Balance Sheet Providing Operational Runway
CRISPR Therapeutics closed 2025 with approximately $1.98 billion in liquidity, which management states is sufficient to fund operations for at least 24 months. That cash cushion means the company is unlikely to need emergency dilutive financing in the near term, giving the pipeline time to generate clinical data. A subsequent convertible notes offering in early 2026 supplemented the position further.
What are the risks to CRSP?
The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The stock also carries high short interest, above 22 percent of shares outstanding as of recent data, reflecting meaningful institutional skepticism about the pace of the commercial ramp.
How is CRSP valued? (as of June 27, 2026 (data reflects most recently available reports through mid-2026))
- Revenue (Full Year 2025, product only): ~$3.5 million
- Revenue (Full Year 2024): ~$37.3 million (primarily collaboration revenue)
- Net Loss (TTM through Q3 2025): ~$488 million
- Operating Loss (Full Year 2025): ~$665 million
- Market Capitalization: ~$4.5 to $5.2 billion (range reflecting recent price movement near $54)
- Cash and Marketable Securities: ~$1.98 billion (as of December 31, 2025)
- P/E Ratio (TTM): Negative (not meaningful; company is unprofitable)
- Short Interest: ~22% of shares outstanding
Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based valuation multiples like P/E are negative and not analytically useful. The company is better evaluated on its cash runway, the pace of Casgevy's commercial adoption, and the risk-adjusted value of its pipeline. Enterprise value of roughly $2.8 billion (market cap less net cash) reflects the market pricing in significant execution uncertainty around both the Casgevy ramp and the broader pipeline, while a wide spread exists between bearish analyst targets near $33 and optimistic targets above $80.
How do you decide if CRSP is a buy?
Rather than asking whether CRSP is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CRSP indirectly through an index or sector ETF before adding more.
For the full picture, see the CRSP stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CRSP against your real portfolio and see your actual exposure before deciding.
The bottom line on CRSP
The bottom line: CRISPR Therapeutics AG's story right now is First-Mover Advantage in Commercial Gene Editing, with revenue (full year 2025, product only) at ~$3.5 million. If you believe that narrative continues, the call is about sizing CRSP sensibly and checking overlap with what you own; if you doubt it (the risk: the commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CRSP with Walnut
Use CRISPR Therapeutics AG as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CRSP a good stock to buy right now?
+
The case for CRISPR Therapeutics AG right now is First-Mover Advantage in Commercial Gene Editing, with revenue (full year 2025, product only) at ~$3.5 million. If you believe that thesis holds, CRSP is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does CRISPR Therapeutics AG do?
+
CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts.
What are the main risks of CRSP?
+
The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The stock also carries high short interest, above 22 percent of shares outstanding as of recent data, reflecting meaningful institutional skepticism about the pace of the commercial ramp.
What does CRISPR Therapeutics do?
+
CRISPR Therapeutics uses its CRISPR/Cas9 gene editing platform to develop medicines for serious diseases. Its only approved product is Casgevy, co-developed with Vertex Pharmaceuticals, which is the world's first CRISPR-based therapy and targets sickle cell disease and transfusion-dependent beta-thalassemia. Its pipeline spans CAR-T cancer therapies, cardiovascular gene editing, and an acquired siRNA program.
Is CRSP a good stock to buy right now?
+
That depends entirely on an investor's risk tolerance and time horizon. CRSP offers exposure to a genuinely first-of-its-kind commercial gene-editing asset and a broad pipeline, but the company is deeply unprofitable, burning several hundred million dollars per year, with Casgevy's commercial ramp proving very slow. Analysts hold widely divergent views, with price targets ranging from around $33 to over $80.
Does CRSP pay a dividend?
+
No. CRISPR Therapeutics does not pay a dividend. The company is pre-profitability with significant annual operating losses, and its capital is directed entirely toward clinical development and the commercial rollout of Casgevy. Investors seeking income from dividends would need to look elsewhere in the biotech or broader healthcare sector.
Who are CRISPR Therapeutics's main competitors?
+
The most direct pure-play competitors are Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and Beam Therapeutics, all of which pursue CRISPR or related gene editing platforms. In CAR-T therapies, CRSP competes with Novartis, Gilead/Kite, and Bristol Myers Squibb. In cardiovascular gene editing, Verve Therapeutics targets overlapping programs. Large pharma companies with gene-editing partnerships represent longer-term competitive threats.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CRSP; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.